Skip to search boxSkip to navigationSkip to main content

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

  • Mahmoud A. Ghannoum(corresponding author)
    ,
  • A. Chen
    ,
  • M. Buhari
    ,
  • J. Chandra
    ,
  • P. K. Mukherjee
    ,
  • D. Baxa
*Corresponding author for this work
  • Case Western Reserve University
    ,
  • Wayne State University
    ,
  • Henry Ford Health System
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Recent studies suggest that differences in antifungal activity among echinocandins may exist. In this study, the activities of three echinocandins (anidulafungin, caspofungin, and micafungin) against Candida parapsilosis isolates from burn unit patients, healthcare workers and the hospital environment were determined. Additionally, the effect of these echinocandins on the cell morphology of caspofungin-susceptible and caspofungin-non-susceptible isolates was assessed using scanning electron microscopy (SEM). The C parapsilosis isolates obtained from patients were susceptible to anidulafungin, but were less so to caspofungin and micafungin. Isolates obtained from healthcare workers or environmental sources were susceptible to all antifungals. SEM data demonstrated that although anidulafungin and caspofungin were equally active against a caspofungin-susceptible C parapsilosis strain, they differed in their ability to damage a caspofungin-non-susceptible strain, for which lower concentrations of anidulafungin (1 mg/L) than of caspofungin (16 mg/L) were needed to induce cellular damage and distortion of the cellular morphology. To determine whether the difference in the antifungal susceptibility of C parapsilosis isolates to anidulafungin as compared to the other two echinocandins could be due to different mutations in the FKS1 gene, the sequences of the 493-bp region of this gene associated with echinocandin resistance were compared. No differences in the corresponding amino acid sequences were observed, indicating that differences in activity between anidulafungin and the other echinocandins are not related to mutations in this region. The results of this study provide evidence that differences exist between the activities of anidulafungin and the other echinocandins.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 274-279 (6 pages)

Journal (Volume, Issue Number)

Clinical Microbiology and Infection (Volume 15, Issue 3)

Publication milestones

  • Published - 2009

Publication status

Published - 2009

ISSN

1198-743X

Publication IDs

  • Scopus: 63249086820
  • PubMed: 19210699
  • ORCID: /0000-0001-5774-819X/work/227133017

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
SciVal
FWCI
2.52
SciVal
Author count
8
SciVal
citations
40
SciVal
Paper percentile
86

PlumX, opens in new tab

Citation count
42
Captures
37

Funding Details

This study was partially supported by funds from Pfizer Pharmaceutical Company. M.A. Ghannoum has acted as a consultant, speaker or received grants and contracts from the following companies: Pfizer, Merck, Novartis, Schering Plough, and Stiefel Pharmaceuticals. P.K. Mukherjee has acted as a consultant, speaker or received grants and contracts from the following companies: Great Lakes Pharmaceuticals, Staval Pharmaceuticals, Gebauer Pharmaceuticals, and Astella. The other authors have no conflict of interest with the studies performed.
FunderFunding numbers
Pfizer Pharmaceutical Company and Islamic Development Bank
-